Meeder Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Meeder Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-73	Closed	-$2K	–	2272
2019 Q2	$2K	Hold	73	–	–	﹤0.01%	1883
2019 Q1	$3K	Buy	73 +8	+12%	+$362	﹤0.01%	1512
2018 Q4	$3K	Buy	65 +15	+30%	+$867	﹤0.01%	1528
2018 Q3	$4K	Buy	50 +30	+150%	+$2.83K	﹤0.01%	1378
2018 Q2	$1.91K	Buy	20 +11	+122%	+$1.16K	﹤0.01%	1423
2018 Q1	$1K	Buy	+9	New	+$978	﹤0.01%	1483

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's VRDN Position: Q3 2019 in Review

Meeder Asset Management sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 73 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in VRDN in Q1 2018 and held it in 6 quarters. The position peaked at $4K in Q3 2018. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

Meeder Asset Management reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
Meeder Asset Management sold 73 Viridian Therapeutics shares in Q3 2019, an estimated $2K.
Meeder Asset Management first reported a position in Viridian Therapeutics in Q1 2018 and held it in 6 quarters.
Meeder Asset Management's Viridian Therapeutics position peaked at $4K in Q3 2018.
33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Meeder Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.